Celcuity Inc. (CELC)
Stock Price:
$7.07 USD
0.12 (1.73%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
72.53M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-7.76M |
| Shares Out |
10.26M |
| EPS (ttm) |
-0.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$7.07 |
| Previous Close |
$6.95 |
| Change ($) |
0.12 |
| Change (%) |
1.73% |
| Day's Open |
7.03 |
| Day's Range |
7.01 - 7.49 |
| Day's Volume |
4,449 |
| 52-Week Range |
4.03 - 24.02 |
More Stats
| Market Cap |
72.53M |
| Enterprise Value |
55.85M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
10.26M |
| Float |
5.44M |
| EPS (basic) |
-0.76 |
| EPS (diluted) |
-0.76 |
| FCF / Share |
-0.65 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
145,987 |
| Short Ratio |
4.60 |
| Short % of Float |
1.52% |
| Beta |
1.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.59 |
| Revenue |
n/a |
| Operating Income |
-8.14M |
| Net Income |
-7.76M |
| Free Cash Flow |
-6.62M |
| Net Cash |
16.68M |
| Net Cash / Share |
1.63 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-23.49% |
| ROE |
-37.51% |
| ROIC |
-213.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.50*
(90.95% upside)
Low
11.0
Current: 7.07
High
16.0
Target: 13.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -7.81 | -7.93 | -5.95 | -3.33 | -2.26 |
| Net Income | -7.36 | -7.48 | -6.25 | -3.31 | -2.26 |
| Shares Outstanding | 10.23 | 10.12 | 7.46 | 6.31 | 5.84 |
| Earnings Per Share | -0.72 | -0.74 | -0.84 | -0.52 | -0.39 |
| Operating Cash Flow | -6.00 | -6.08 | -4.95 | -2.89 | -1.98 |
| Capital Expenditures | -0.38 | -0.63 | -0.24 | -0.04 | -0.08 |
| Free Cash Flow | -6.38 | -6.70 | -5.19 | -2.93 | -2.06 |
| Cash & Equivalents | 18.76 | 24.92 | 24.27 | 5.91 | 5.12 |
| Total Debt | 0.26 | 0.03 | - | - | - |
| Net Cash / Debt | 18.50 | 24.89 | 24.27 | 5.91 | 5.12 |
| Assets | 20.28 | 26.03 | 31.97 | 6.06 | 5.30 |
| Liabilities | 0.98 | 0.68 | 0.58 | 0.45 | 0.28 |
| Book Value | 19.30 | 25.35 | 31.39 | 5.61 | 5.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Celcuity Inc. |
| Country |
United States |
| Employees |
27 |
| CEO |
Brian F. Sullivan |
Stock Information
| Ticker Symbol |
CELC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: CELC |
| IPO Date |
September 20, 2017 |
Description
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELx MP test to diagnose 12 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.